indapamide (lozol) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Indapamide is an antihypertensive and a diuretic. It contains both a polar sulfamoyl chlorobenzamide moiety and a lipid- soluble methylindoline moiety. Indapamide blocks the slow component of delayed rectifier potassium current (IKs) without altering the rapid component (IKr) or the inward rectifier current. Specifically it blocks or antagonizes the action the proteins KCNQ1 and KCNE1. Indapamide is also thought to stimulate the synthesis of the vasodilatory hypotensive prostaglandin PGE2. Indapamide is used for the treatment of hypertension, alone or in combination with other antihypertensive drugs, as well as for the treatment of salt and fluid retention associated with congestive heart failure or edema from pregnancy (appropriate only in the management of edema of pathologic origin during pregnancy when clearly needed). Also used for the management of edema as a result of various causes.   NCATS

Chemistry

  • SMILES: CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(Cl)C=C3)S(N)(=O)=O
  • InChIKey: NDDAHWYSQHTHNT-UHFFFAOYSA-N
  • Mol. Mass: 365.835
  • ALogP: 2.08
  • ChEMBL Molecule:
    indapamide  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$0.0458 - $0.1280

United States

$0.1397 - $0.3757
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

cardide sr | ethibide xl | flupamid | indaflex | indamide | indamol | indapamid | indapamida | indapamide | (+/-)-indapamide | indapamide hemihydrate | indapamidum | indaxa 2.5 | indipamide | indipam xl | lozol | mapemid xl | metindamide | natrilix | natrilix sr | nindaxa 2.5 | opumide 2.5 | rawel xl | tensaid xl | varbim xl | veroxil

Organizations (66)

Research & Development (55)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (20)

Approved Indications (2)


 

Heart Failure (approved 1998)

Hypertension

Experimental Indications - Clinical Trial Phases 1-4 (19)


 

Atherosclerosis (Phase 4)

Blood Pressure (Phase 1)

Cerebral Hemorrhage (Phase 3)

Cerebral Small Vessel Diseases (Phase 3)

Cognitive Dysfunction (Phase 3)

Dementia, Vascular (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Essential Hypertension (Phase 3)

Healthy Volunteers (Phase 1)

Hemorrhage (Phase 4)

Hypertension ()

Kidney Calculi (Phase 2)

Kidney Diseases (Phase 2)

Multiple Sclerosis, Chronic Progressive (Phase 2)

Pharmacogenetics (Phase 4)

Renal Insufficiency (Phase 4)

Stroke (Phase 3)

Therapeutic Equivalency (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 43
  • # of Trial Organizations: 55

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue